COVID-19 in hematopoietic cell transplant recipients

Basit Öğe Kaydı
dc.authorid0000-0003-1864-0316
dc.authorid0000-0003-3312-8476
dc.authorid0000-0003-4304-9245
dc.authorid0000-0002-3285-417X
dc.authorid0000-0001-9962-8882
dc.authorid0000-0003-2131-2866
dc.authorid0000-0003-0825-1851
dc.authorscopusid6602557128
dc.authorscopusid24471549000
dc.authorscopusid57189243089
dc.authorscopusid56545735000
dc.authorscopusid56370690600
dc.authorscopusid14022986200
dc.authorscopusid55672209100
dc.authorwosidBasturk, Abdulkadir/B-1962-2018
dc.authorwosidBERBER, Ilhami/ABI-6231-2020
dc.authorwosidBaşcı, Semih/AAB-4823-2021
dc.authorwosidHacıbekiroğlu, Tuba/ABH-2380-2020
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidYigenoglu, Tugce/ABF-6595-2021
dc.contributor.authorAltuntaş, Fevzi
dc.contributor.authorAta, Naim
dc.contributor.authorYigenoğlu, Tuğçe Nur
dc.contributor.authorBaşcı, Semih
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorKorkmaz, Serdal
dc.contributor.authorBirinci, Şuayip
dc.contributor.authorTurgut, Burhan
dc.date.accessioned2022-05-11T14:40:00Z
dc.date.available2022-05-11T14:40:00Z
dc.date.issued2021
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractIn this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients (n = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A cohort of age and comorbid disease-matched hospitalized COVID-19 patients with hematological malignancy but not underwent HCT (n = 465), and another cohort of age and comorbid disease-matched hospitalized COVID-19 patients without cancer (n = 497) were also included in the study for comparison. Case fatality rate (CFR) was 5.6% in patients without cancer, 11.8 in patients with hematological malignancy and 15.6% in HCT recipients. The CFR in HCT recipients who were not receiving immunosuppressive agents at the time of COVID-19 diagnosis was 11.5%, whereas it was 33% in HCT recipients who were receiving an immunosuppressive agent at the time of COVID-19 diagnosis. In conclusion, our study reveals that for the current pandemic, HCT recipients, especially those receiving immunosuppressive drugs, constitute a special population of cancer patients.
dc.identifier.doi10.1038/s41409-020-01084-x
dc.identifier.endpage955
dc.identifier.issn0268-3369
dc.identifier.issn1476-5365
dc.identifier.issue4en_US
dc.identifier.pmid33110186
dc.identifier.scopus2-s2.0-85094131594
dc.identifier.scopusqualityQ1
dc.identifier.startpage952
dc.identifier.urihttps://doi.org/10.1038/s41409-020-01084-x
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8828
dc.identifier.volume56
dc.identifier.wosWOS:000584556900001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorTurgut, Burhan
dc.language.isoen
dc.publisherSpringernature
dc.relation.ispartofBone Marrow Transplantation
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleCOVID-19 in hematopoietic cell transplant recipients
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
8828.pdf
Boyut:
456.61 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu